Toshiba, AOI Bio win Japan patent for allosteric pathway prediction technology using SQBM+

• Toshiba secured a Japan patent for an allosteric pathway prediction device aimed at identifying allosteric sites in hard-to-drug proteins.
• The patent, No. 7908389, was registered on Aug. 10, 2026, with AOI Biosciences listed as a co-applicant.
• The technology uses Toshiba’s SQBM+ quantum-inspired optimization to analyze protein structures, targeting faster allosteric-site identification for drug discovery.
• Validation against known allosteric sites showed accuracy above 80%, supporting potential expansion of druggable targets beyond active-site approaches.
• Plans include broader rollout of an allosteric-site prediction service to pharmaceutical clients, with additional joint drug-discovery research.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Toshiba Corporation published the original content used to generate this news brief on September 03, 2026, and is solely responsible for the information contained therein.